UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
(State or other jurisdiction |
(Commission |
(IRS Employer |
of incorporation) |
File Number) |
Identification No.) |
|
|
|
|
||
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain officers; Compensatory Arrangements of Certain Officers.
On June 6, 2024, Aspira Women’s Health Inc. (the “Company”) entered into a second amendment (the “Second Amendment”) to its employment agreement with Torsten Hombeck, the Company’s Chief Financial Officer. The Second Amendment is effective as of June 1, 2024.
Pursuant to the terms of the Second Amendment, Dr. Hombeck was appointed as the Company's Corporate Secretary and his annual base salary was increased to $375,000 from $325,000 as of June 1, 2024.
The foregoing description of the Second Amendment is qualified in its entirety by reference to the full text of the Second Amendment, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
|
Exhibit No. |
Description |
10.1 |
|
104 |
Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
ASPIRA WOMEN’S HEALTH INC. |
|
|
|
Date: June 7, 2024 |
By: |
/s/ Nicole Sandford |
|
|
Nicole Sandford |
|
|
Chief Executive Officer |
EX.10.1
SECOND AMENDMENT
TO
Employment Agreement
This SECOND AMENDMENT (the “Second Amendment”), dated as of June 5, 2024, (the “Second Amendment Date”) to the Employment Agreement (the “Employment Agreement”), dated May 16, 2023 (“Effective Date”), is made by and among Dr. Torsten Hombeck (“Executive”) and Aspira Women’s Health Inc. and is effective as of June 1, 2024, for itself and on behalf of its wholly owned affiliates (collectively “Aspira” or “Company”).
RECITALS
NOW, THEREFORE, in consideration of these premises and the covenants set forth below, and for good and valuable consideration, Executive and Company hereby amend the Agreements as follows:
AGREEMENT
“The Company will employ Executive as its Chief Financial Officer and Corporate Secretary.”
2. Base and Bonus:as follows:
The Company will pay Executive a base salary of $375,000.00 on an annualized basis, payable in accordance with the Company’s standard payroll policies, including compliance with applicable tax withholding requirements based on Executive’s state of residence.
[Signature page to follow]
IN WITNESS WHEREOF, the Parties have executed this Amendment on the date first written above.
Dr. Torsten Hombeck
|
ASPIRA WOMEN’S HEALTH INC.
|
By: _/s/ Torsten Hombeck Name: Dr. Torsten Hombeck_ Title: _CFO___________ |
By: _/s/ Nicole Sandford Name: Nicole Sandford_ Title: _CEO___________ |
Document and Entity Information |
Jun. 06, 2024 |
|---|---|
| Cover [Abstract] | |
| Entity Registrant Name | Aspira Women’s Health Inc. |
| Security Exchange Name | NASDAQ |
| Amendment Flag | false |
| Entity Central Index Key | 0000926617 |
| Document Type | 8-K |
| Document Period End Date | Jun. 06, 2024 |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-34810 |
| Entity Tax Identification Number | 33-0595156 |
| Entity Address, Address Line One | 12117 Bee Caves Road |
| Entity Address, Address Line Two | Building III |
| Entity Address, Address Line Three | Suite 100 |
| Entity Address, City or Town | Austin |
| Entity Address, State or Province | TX |
| Entity Address, Postal Zip Code | 78738 |
| City Area Code | (512) |
| Local Phone Number | 519-0400 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, par value $0.001 per share |
| Trading Symbol | AWH |
| Entity Emerging Growth Company | false |